PE20121063A1 - Anticuerpos anti-cdcp1 humanizados - Google Patents

Anticuerpos anti-cdcp1 humanizados

Info

Publication number
PE20121063A1
PE20121063A1 PE2012000273A PE2012000273A PE20121063A1 PE 20121063 A1 PE20121063 A1 PE 20121063A1 PE 2012000273 A PE2012000273 A PE 2012000273A PE 2012000273 A PE2012000273 A PE 2012000273A PE 20121063 A1 PE20121063 A1 PE 20121063A1
Authority
PE
Peru
Prior art keywords
seq
humanized anti
cdcp1
antibodies
antibody
Prior art date
Application number
PE2012000273A
Other languages
English (en)
Inventor
Johannes Auer
Birgit Bossenmaier
Guy Georges
Alexander Lifke
Ekkehard Moessner
Gerhard Niederfellner
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of PE20121063A1 publication Critical patent/PE20121063A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

REFERIDA A UN ANTICUERPO QUE SE UNE ESPECIFICAMENTE A LA CDCP1 HUMANIZADO QUE COMPRENDE UN DOMINIO VARIABLE DE CADENA LARGA (VH) DE SEQ ID NO:3 Y UN DOMINIO VARIABLE DE CADENA CORTA (VL) DE SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23 O SEQ ID NO:24, DONDE DICHO ANTICUERPO ES DEL SUBGRUPO IgG1 HUMANO Y ESTA GLUCOSILADO CON UNA CADENA DE AZUCAR EN Asn297, ESTANDO LA CANTIDAD DE FUCOSA DENTRO DE DICHO AZUCAR EN UNA CANTIDAD DEL 65% O MENOS. DICHOS ANTICUERPOS SON UTILES EN EL TRATAMIENTO DEL CANCER
PE2012000273A 2009-08-28 2010-08-26 Anticuerpos anti-cdcp1 humanizados PE20121063A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09011046 2009-08-28
EP10000972 2010-02-01

Publications (1)

Publication Number Publication Date
PE20121063A1 true PE20121063A1 (es) 2012-08-09

Family

ID=43086176

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000273A PE20121063A1 (es) 2009-08-28 2010-08-26 Anticuerpos anti-cdcp1 humanizados

Country Status (23)

Country Link
US (2) US8394928B2 (es)
EP (1) EP2470567A1 (es)
JP (1) JP5647687B2 (es)
KR (1) KR101495407B1 (es)
CN (1) CN102482357B (es)
AR (1) AR077973A1 (es)
AU (1) AU2010288879A1 (es)
BR (1) BR112012004221A2 (es)
CA (1) CA2770161A1 (es)
CL (1) CL2012000524A1 (es)
CO (1) CO6511201A2 (es)
CR (1) CR20120038A (es)
EC (1) ECSP12011701A (es)
IL (1) IL217919A0 (es)
MA (1) MA33537B1 (es)
MX (1) MX2012002458A (es)
NZ (1) NZ597664A (es)
PE (1) PE20121063A1 (es)
RU (1) RU2571207C2 (es)
SG (1) SG178886A1 (es)
TW (1) TWI412375B (es)
UA (1) UA106890C2 (es)
WO (1) WO2011023389A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI412375B (zh) * 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
TW201113037A (en) * 2009-08-28 2011-04-16 Hoffmann La Roche Antibodies against CDCP1 for the treatment of cancer
RU2013139267A (ru) 2011-02-10 2015-03-20 Рош Гликарт Аг Улучшенная иммунотерапия
AR092044A1 (es) 2012-08-07 2015-03-18 Roche Glycart Ag Inmunoterapia mejorada
PT2928923T (pt) 2012-12-10 2020-03-27 Biogen Ma Inc Anticorpos antígenos 2 de células dendríticas anti-sangue e os seus usos
WO2014172448A2 (en) * 2013-04-17 2014-10-23 Anaptysbio, Inc. Antibodies directed against activin receptor type ii (actrii)
WO2015082446A1 (en) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-cdcp1 antibody and a taxane
CN106163560A (zh) 2014-01-24 2016-11-23 亨利·M·杰克逊军事医学促进基金会 针对亨德拉和尼帕病毒的f糖蛋白的抗体
US20170158753A1 (en) * 2014-06-25 2017-06-08 Integrated Biotherapeutics, Inc. Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species
JP7350313B2 (ja) 2016-12-16 2023-09-26 ブルーフィン バイオメディシン， インコーポレイテッド 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法
US10928391B2 (en) * 2017-06-06 2021-02-23 The Cleveland Clinic Foundation CD318 as a marker for, and CD318 inhibition as a treatment for, autoimmune disease
WO2019084319A1 (en) 2017-10-25 2019-05-02 The Regents Of The University Of California ANTIBODIES AGAINST CDCP1 FOR THE TREATMENT AND DETECTION OF CANCER
MX2021005377A (es) 2018-11-09 2021-09-14 Beth Israel Deaconess Medical Ct Inc Terapias dirigidas a cdcp1.
MX2021009119A (es) * 2019-02-01 2022-01-18 Fond Per Listituto Oncologico Di Ricerca Ior Metodos de tratamiento contra el cancer de prostata resistente a la castracion.
CN118440202A (zh) 2019-12-27 2024-08-06 凯奥目生物科学株式会社 抗cdcp1抗体
KR102911451B1 (ko) * 2022-05-24 2026-01-09 건국대학교 글로컬산학협력단 Rps3 결합 단클론 항체 및 이의 용도
CN117264055A (zh) * 2022-06-14 2023-12-22 上海恒润达生生物科技股份有限公司 一种特异性结合人cd318的vhh抗体或其抗原结合片段及其制备方法和应用
KR20250028265A (ko) * 2022-06-20 2025-02-28 쓰추안 휘위 파머슈티컬 컴퍼니., 리미티드. 항체 및 이의 용도
CN119836306A (zh) 2022-07-15 2025-04-15 费恩治疗有限公司 与cdcp1结合的抗体药物缀合物和其用途
KR20240057529A (ko) * 2022-10-24 2024-05-03 주식회사 노벨티노빌리티 신규 항-cdcp1 항체 및 이의 용도
WO2025199124A1 (en) * 2024-03-19 2025-09-25 Tavotek Lab Inc Antibodies targeting cd318 (cdcp1) and uses thereof
WO2025207944A1 (en) * 2024-03-29 2025-10-02 Sidewinder Therapeutics, Inc. Fgfr3-iiib-binding antibodies
WO2025262641A1 (en) 2024-06-19 2025-12-26 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof
WO2026078443A1 (en) 2024-10-11 2026-04-16 Pheon Therapeutics Ltd. Antibody drug conjugates that bind cdcp1 and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
EP0938506B1 (en) * 1996-07-16 2003-11-05 Plückthun, Andreas, Prof. Dr. Immunoglobulin superfamily domains and fragments with increased solubility
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
CN1329061A (zh) 2000-06-19 2002-01-02 上海博德基因开发有限公司 一种新的多肽——人g蛋白亚基9.46和编码这种多肽的多核苷酸
WO2002004508A1 (de) 2000-07-07 2002-01-17 Boehringer Ingelheim International Gmbh Tumorassoziiertes antigen (b345), gekennzeichnet durch eine aminosäuresequenz wie in seq. id. no. 4
NZ581474A (en) * 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
DE10242146A1 (de) 2002-09-04 2004-03-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper zur Identifizierung und/oder Isolierung von hämatopoetischen Stammzellen
CZ308720B6 (cs) 2003-01-22 2021-03-24 Roche Glycart Ag Fúzní konstrukty a jejich použití pro přípravu protilátek se zvýšenou vazebnou afinitou k receptorům Fc a efektorovou funkcí
AU2004213568A1 (en) 2003-02-19 2004-09-02 Novartis Ag Glycoprotein antigen SIMA135 expressed in metastatic human tumor cells
EP1648511A1 (en) 2003-07-29 2006-04-26 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with enhanced effector function
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
AU2004273791A1 (en) 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
GB0324656D0 (en) 2003-10-22 2003-11-26 Celltech R&D Ltd A protein involved in ovarian cancer
PT1692182E (pt) 2003-11-05 2010-05-13 Roche Glycart Ag Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
US20080008719A1 (en) * 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
WO2007024249A2 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
CA2605697A1 (en) 2005-04-26 2006-11-02 Bioren, Inc. Method of producing human igg antibodies with enhanced effector functions
WO2007005502A2 (en) 2005-06-30 2007-01-11 Applera Corporation Methods and compositions for treating diseases targeting cdcp1
RU2482132C2 (ru) 2005-08-26 2013-05-20 Роше Гликарт Аг Модифицированные антигенсвязывающие молекулы с измененной клеточной сигнальной активностью
JP2007112734A (ja) * 2005-10-19 2007-05-10 Chugai Pharmaceut Co Ltd 抗ｃｄｃｐ１抗体を含有する癌細胞増殖抑制剤
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
TWI412375B (zh) * 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體

Also Published As

Publication number Publication date
US20130209455A1 (en) 2013-08-15
WO2011023389A1 (en) 2011-03-03
MA33537B1 (fr) 2012-08-01
SG178886A1 (en) 2012-04-27
US8394928B2 (en) 2013-03-12
AR077973A1 (es) 2011-10-05
EP2470567A1 (en) 2012-07-04
HK1167412A1 (en) 2012-11-30
BR112012004221A2 (pt) 2016-11-29
CO6511201A2 (es) 2012-08-31
CN102482357B (zh) 2014-06-11
CL2012000524A1 (es) 2012-08-17
TW201110983A (en) 2011-04-01
NZ597664A (en) 2013-03-28
UA106890C2 (uk) 2014-10-27
US9346886B2 (en) 2016-05-24
CA2770161A1 (en) 2011-03-03
RU2012111708A (ru) 2013-10-10
AU2010288879A1 (en) 2012-02-02
CN102482357A (zh) 2012-05-30
ECSP12011701A (es) 2012-03-30
RU2571207C2 (ru) 2015-12-20
KR101495407B1 (ko) 2015-02-24
US20110052582A1 (en) 2011-03-03
MX2012002458A (es) 2012-03-14
TWI412375B (zh) 2013-10-21
JP2013502904A (ja) 2013-01-31
JP5647687B2 (ja) 2015-01-07
CR20120038A (es) 2012-04-18
KR20120089658A (ko) 2012-08-13
IL217919A0 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
PE20120427A1 (es) Anticuerpos contra el receptor de cgrp humano
PE20221007A1 (es) Anticuerpos anti-receptor de transferrina con afinidad disenada
PE20071312A1 (es) Anticuerpos contra il-22 humana
PE20130560A1 (es) Anticuerpos bivalentes biespecificos anti-vegf/anti-ang-2
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados
PE20130479A1 (es) Anticuerpos reactivos con b7-h3, fragmentos inmulogicamente activos de los mismos y usos de los mismos
NZ600262A (en) Anti-her3 antibodies and uses thereof
PE20091196A1 (es) Anticuerpos contra el vegf completamente humano, composiciones y metodos
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
GB2488091A (en) Humanized anti-interleukin 3 receptor alpha chain antibodies
AR064620A1 (es) Anticuerpos contra el receptor del factor de crecimiento similar a la insulina i y l a utilizacion de los mismos
PE20121398A1 (es) Anticuerpos ligantes preferentemente al dominio extracelular 4 de csf1r humano
PE20110306A1 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3)
NZ616382A (en) Antibodies specific to cadherin-17
MX2010007935A (es) Anticuerpo monoclonal humanizado anti-nkg2a humano.
SV2011003880A (es) Anticuerpos humanos de alta afinidad para el receptor il-4 humano
ES2722824T3 (es) Anticuerpos monoclonales contra el inhibidor de la ruta del factor tisular (TFPI)
MX2012003825A (es) Anticuerpos anti igg reactivos no cruzados.
AR092216A1 (es) Formulaciones estables de anticuerpos contra tslp
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
PE20150222A1 (es) Anticuerpos multiespecificos
NZ701709A (en) Monoclonal antibodies to progastrin and their uses
NZ583605A (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
GB201005064D0 (en) Biological products
PE20121034A1 (es) Anticuerpos anti-factor d humanizados

Legal Events

Date Code Title Description
FC Refusal